ReviewInternational journal of molecular sciences2023
Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Microvascular invasion is associated with poor prognosis in renal cell carcinoma: a retrospective cohort study and meta-analysis.Frontiers in oncology · 2024Pooled it
- Ginsenoside Rg1 ameliorates renal ischemia-reperfusion injury by inhibiting FABP1-regulated Nrf2/HO-1 pathway.Renal failure · 2026Article
- Identification and external validation of a prognostic signature based on bone morphogenetic protein-related mRNAs for kidney renal clear cell carcinoma.Discover oncology · 2026Article
- A CT-based radiomics model for noninvasive prediction of MMP9 expression and prognostic evaluation in renal cell carcinoma.Medicine · 2026Observational
- Two decades of research on drug resistance in renal cell carcinoma.Discover oncology · 2026Article
- Tetrandrine-based in situ vaccination via multifunctional Mn²⁺-hyaluronic acid hydrogel loading gelatinase-responsive nanoparticles.Journal of nanobiotechnology · 2026Article
- Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma.Discover oncology · 2026Article
- PPP4C-related metastasis genes serve as a prognostic signature and potential therapeutic target in renal cell carcinoma.Discover oncology · 2026Article
- Pan-cancer multi-omics profiling of gasdermins identifies GSDMD as an immune-related prognostic biomarker in kidney renal clear cell carcinoma.Discover oncology · 2026Article
- A multi-omics prognostic model and functional validation ofTranslational andrology and urology · 2026Article
- Hypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives.Biomedicines · 2026Review
- Kidney-Lung Crosstalk in Acute Nephrologic Involvement: Mechanisms, Complement Activation, and Implications for Multiorgan Dysfunction.Life (Basel, Switzerland) · 2026Review
- IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma.Scientific reports · 2026Article
- MUC1/CA15-3 identifies a clear cell renal carcinoma characterized by Sunitinib response with a specific metabolic signature.Clinical and experimental medicine · 2026Article
- Integrating machine learning and multi-omics analysis to explore Treg-associated programmed cell death features in clear cell renal cell carcinoma.Cancer cell international · 2026Article
- Tumor-associated neutrophils in renal cell carcinoma.Frontiers in immunology · 2026Review
- A new perspective on the pathophysiology of kidney diseases: the intracellular complement system- "complosome".Frontiers in nephrology · 2026Review
- Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage.Frontiers in immunology · 2026Review
- Identification of cancer-associated fibroblast signature genes for potential biomarkers in cholangiocarcinoma: a Mendelian randomization study.Discover oncology · 2025Article
- Cuproptosis-related gene DLD expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma.Discover oncology · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The crosstalk among the complement system, immune cells, and mediators of inflammation provides an efficient mechanism to protect the organism against infections and support the repair of damaged tissues. Alterations in this complex machinery play a role in the pathogenesis of different diseases. Core complement proteins C3 and C5, their activation fragments, their receptors, and their regulators have been shown to be active intracellularly as the complosome. The kidney is particularly vulnerable to complement-induced damage, and emerging findings have revealed the role of complement system dysregulation in a wide range of kidney disorders, including glomerulopathies and ischemia-reperfusion injury during kidney transplantation. Different studies have shown that activation of the complement system is an important component of tumorigenesis and its elements have been proved to be present in the TME of various human malignancies. The role of the complement system in renal cell carcinoma (RCC) has been recently explored. Clear cell and papillary RCC upregulate most of the complement genes relative to normal kidney tissue. The aim of this narrative review is to provide novel insights into the role of complement in kidney disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.